CUE Cue Biopharma
- 1.650
- +0.020+1.22%
Cue Biopharma News
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Express News | Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Express News | Cue Biopharma Inc - Expect Current Cash and Cash Equivalents to Fund Ops Into First Qtr of 2025
Cue Biopharma | 10-Q: Quarterly report
Express News | Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Express News | Cue Biopharma, Inc. Q1 Basic EPS USD -0.25
Express News | Cue Biopharma, Inc. Q1 Operating Expenses USD 14.385 Million
Express News | Cue Biopharma, Inc. Q1 Collaboration Revenue USD 1.717 Million
Express News | Cue Biopharma, Inc. Q1 Net Income USD -12.347 Million
Cue Biopharma 1Q Loss/Shr 25c >CUE
Cue Biopharma 1Q Loss/Shr 25c >CUE
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersTwist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out to
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,
Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning
Analysis
Price Target
No Data
